Display Settings:

Format

Send to:

Choose Destination
Int J Antimicrob Agents. 2010 Sep;36(3):197-204. doi: 10.1016/j.ijantimicag.2010.04.013. Epub 2010 Jun 16.

Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia.

Author information

  • 1JMI Laboratories, 345 Beaver Kreek Centre, Ste A, North Liberty, IA 52317, USA. ronald-jones@jmilabs.com

Abstract

Pneumonia is a major infectious disease associated with significant morbidity, mortality and utilisation of healthcare resources. Streptococcus pneumoniae is the predominant pathogen in community-acquired pneumonia (CAP), accounting for 20-60% of bacterial cases. Emergence of multidrug-resistant S. pneumoniae has become a significant problem in the management of CAP. Although pneumococcal conjugate vaccine usage in children has led to significant decreases in morbidity and mortality due to S. pneumoniae in all age groups, disease management has been further complicated by the unexpected increase in resistant serotypes, such as 19A, in some regions. Until rapid and accurate diagnostic tests become available, initial treatment of CAP will remain empirical. Thus, selection of appropriate antimicrobial therapy for CAP must be based on prediction of the most likely pathogens and their local antimicrobial susceptibility patterns. This article reviews information on antimicrobial resistance patterns amongst S. pneumoniae and implications for managing CAP.

Copyright (c) 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

PMID:
20558045
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk